$7.390
-0.128 (-1.73%)Al cierre
Noticias de XGN
Eventos de XGN
Company Raises 2026 Revenue Guidance to $72M-$75M
Consensus $71.67M. The company said, "The Company increased full-year 2026 revenue guidance to $72 million - $75 million compared to previous guidance of $70 million - $73 million."
Exagen Reports Q2 Revenue of $19.94M, Beating Consensus
Reports Q2 revenue $19.94M, consensus $17.87M. "We continue to advance Exagen's unique mission to bring clarity to autoimmune disease," said John Aballi, President and Chief Executive Officer. "Second quarter financial results demonstrate the progress we're making in improving the growth and operating profile of our business, putting us within reach of sustainable profitability and cash generation. At the same time, we are building on Exagen's leadership in autoimmune diagnostics through continued investment in clinical evidence generation, pipeline innovation and AI-powered tools that support rheumatology workflows to strengthen our role in rheumatology decision-making."
Spero Therapeutics Appoints Debra Jeske Zack as Chief Medical Officer
Spero Therapeutics (SPRO) announced the appointment of Debra Jeske Zack as chief medical officer. Zack will lead Spero's clinical development strategy and organization as the company advances its immunology program. Most recently, Zack served as chief medical officer of Exagen (XGN).
Exagen Q1 Revenue $17.31M Beats Expectations
Reports Q1 revenue $17.31M, consensus $16.41M. "First quarter results establish a solid start to 2026, reflecting our team's disciplined execution and effective revenue cycle management," said John Aballi, President and CEO. "Exagen is uniquely committed to providing clarity for autoimmune patients and confidence for clinicians. We have built a foundation to expand our reach and advance innovation in a market with significant unmet need."
Company Expects Full-Year 2026 Revenue of $70M to $73M
The company said, "The Company continues to expect full-year 2026 revenue of $70 million to $73 million."
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.